# Rapamycin for Prevention of Chronic Graft-Versus-Host Disease

> **NCT00623012** · PHASE1,PHASE2 · TERMINATED · sponsor: **Yale University** · enrollment: 2 (actual)

## Conditions studied

- Graft Versus Host Disease

## Interventions

- **DRUG:** Rapamycin
- **DRUG:** Tacrolimus

## Key facts

- **NCT ID:** NCT00623012
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2017-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00623012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00623012, "Rapamycin for Prevention of Chronic Graft-Versus-Host Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00623012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*